1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)

Authors :: Stefan Scherer
David Miles
Arlene Chan
Paul Delmar
S. de Haas
Javier Cortes
Luc Dirix
Gilles Romieu
Source :: European Journal of Cancer. 47:S176
Publication Year :: 2011
Publisher :: Elsevier BV, 2011.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Bevacizumab
business.industry
First line
HER2 negative
medicine.disease
Metastatic breast cancer
Docetaxel
Internal medicine
medicine
Polymorphism analysis
business
medicine.drug

Full Text Access

Tools